About Ferrlecit

What is Ferrlecit?

Ferrlecit is an intravenous (IV) iron replacement product for the treatement of iron deficiency anemia in patients 6 years and older with chronic kidney disease receiving chronic hemodialysis (HD) and supplemental epoetin therapy.

Turn to Ferrlecit for...

Experience
  • Established efficacy for both initial repletion and IV iron therapy after repletion treatment1,2
  • Established efficacy in ESA-resistant patients3
Confidence Support
  • One-stop access to reimbursement support services through 1-800-847-0069 the Renassist Helpline.
  • Support and tools to serve your reimbursement needs.
  • Education resources for patients and healthcare professionals

Learn about Ferrlecit dosing and administration

A proven choice to fit your anemia treatment needs1,2

  • Established efficacy and safety—10+ years of clinical experience
  • Support for your dialysis center—professional and patient education and reimbursement resources.
Important Safety Information for Ferrlecit

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferrlecit (sodium ferric gluconate) in post marketing experience. Patients may present with shock, clinically significant hypotension, loss of consciousness, or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferrlecit administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferrlecit when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
  • Ferrlecit is contraindicated in patients with known hypersensitivity to Ferrlecit.
  • Ferrlecit may cause clinically significant hypotension. Administration of Ferrlecit may augment hypotension caused by dialysis and usually resolves within one to two hours. Monitor patients for sign and symptoms of hypotension during and following administration.
  • Do not administer to patients with evidence of iron overload.
  • Ferrlecit contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with serious adverse events and death in pediatric patients. Caution should be exercised when Ferrlecit is administered to a pregnant or nursing woman.
  • The most commonly reported adverse reactions (≥10%):
    • In adult patients were nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps and pain.
    • In patients 6 to 15 years of age the most common adverse reactions (≥10%) were hypotension, headache, hypertension, tachycardia and vomiting.

For more information on Ferrlecit, please see full Prescribing Information.

Ferrlecit is a registered trademark of A. Nattermann & Cie. GmbH.

References:

1. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis. 1999;33:471-482.

2. Bolaños L, Castro P, Falcón TG, Mouzo R, Varela JM. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol. 2002;22:67-72.

3. Ferrlecit® Prescribing Information, sanofi-aventis U.S. LLC.

4. Michael B, Coyne DW, Fishbane S, et al; for the Ferrlecit® Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839.